App-Quantinova.ai

A phase 2 trial of TRC105 with bevacizumab for bevacizumab refractory glioblastoma.

Manmeet Singh Ahluwalia - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Glioblastoma

Bevacizumab

Phase 1, multicenter, open-label, dose-escalation, study of marizomib (MRZ) and bevacizumab (BEV) in WHO grade IV malignant glioma (G4 MG).

Daniela Annenelie Bota - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gliomas

Bevacizumab

A clinical variable-based predictive model of delayed clearance of high dose methotrexate (HDMTX) in patients (pts) with primary CNS lymphoma (PCNSL).

Yu Yuan - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Primary central nervous system lymphoma

Methotrexate

Safety and antitumor activity of hypofractionated stereotactic irradiation (HFSRT) with pembrolizumab (Pembro) and bevacizumab (Bev) in patients (pts) with recurrent high grade gliomas: Preliminary results from phase I study.

Solmaz Sahebjam - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Anaplastic astrocytoma

Pembrolizumab

Phase I study of single agent ibrutinib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL).

Christian Grommes - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

CNS lymphoma

Ibrutinib

Radiologic progression types are treatment specific: An exploratory analysis of a phase 3 study of bevacizumab plus radiotherapy plus temozolomide for patients with newly diagnosed glioblastoma (AVAglio).

Martha Nowosielski - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Glioblastoma

Temozolomide

Polymorphisms risk modeling for vascular toxicity in patients with glioblastoma treated on NRG Oncology/RTOG 0825.

Renke Zhou - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Glioblastoma

N/A

Inter-interpreter reliability of neuropathological assessment of disease status after early repeat resection for suspected recurrent glioblastoma.

Matthias Holdhoff - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Glioblastoma

N/A

Bendamustine for anaplastic gliomas.

Marc C. Chamberlain - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Anaplastic oligodendroglial tumors

Bendamustine

Effect of controlled intratumoral viral delivery of Ad-RTS-hIL-12 + oral veledimex in subjects with recurrent or progressive glioma.

Francois M. Lebel - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gliomas

Ad-RTS-hIL-12

Genetic landscape of extreme responders with anaplastic oligodendroglioma: NRG Oncology/RTOG 9402.

Matthias Holdhoff - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Anaplastic oligodendroglial tumors

N/A

Phase 1/2 trial of bevacizumab plus TPI 287, a brain penetrable anti-microtubule agent, in patients with recurrent glioblastoma.

Samuel Aaron Goldlust - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Glioblastoma

Bevacizumab

Comparison of molecular alteration in glioblastoma tumors from old and young patients.

Joanne Xiu - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Glioblastoma

N/A

Oncogenic correlates of epilepsy in glioblastoma.

Sharon Berendsen - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Glioblastoma

N/A

Phase IB trial of carboxyamidotriazole orotate (CTO) and radiotherapy (RT) with concurrent and adjuvant temozolomide (TMZ) in newly diagnosed glioblastoma (GBM).

Antonio Marcilio Padula Omuro - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Glioblastoma

CAI orotate

Patient survival on the dose escalation phase of the Oncolytic Polio/Rhinovirus Recombinant (PVSRIPO) against WHO grade IV malignant glioma (MG) clinical trial compared to historical controls.

Annick Desjardins - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gliomas

Bevacizumab

Overall survival in patients with glioblastoma before and after bevacizumab approval.

Derek Richard Johnson - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Glioblastoma

Bevacizumab

Phase I/II study of VAL-083 in patients with recurrent glioblastoma.

Kent C. Shih - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Glioblastoma

Bevacizumab

Multicenter Phase IB trial of carboxyamidotriazole orotate (CTO) combined with temozolomide (TMZ) for recurrent glioblastoma (GBM) and other malignant gliomas (MG).

Xuling Lin - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Glioblastoma

CAI orotate

PSMA ADC for progressive glioblastoma: Phase II Brown University Oncology Research Group Study.

Heinrich Elinzano - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Glioblastoma

Temozolomide

Filters

255783 Abstracts